Health Care • Biotechnology: Pharmaceutical Preparations
$7.22 ▲ +0.13
(+1.83%)
MKT CAP: $370.2M • VOL: 682.4K
52W L $4 52W H $14
EBS // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $742.9M | $1.04B | $1.05B |
| YoY Revenue Growth % | -28.8% | -0.5% | — |
| Gross Profit | $416.7M | $362.3M | — |
| Gross Margin % | 56.1% | 34.7% | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | $100.1M | -$108.7M | -$726.4M |
| Operating Margin % | 13.5% | -10.4% | -69.2% |
| Net Income (GAAP) | $52.6M | -$190.6M | -$760.5M |
| EBITDA (Normalized) | $111.1M | -$90.4M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | $170.6M | $58.7M | -$206.3M |
| Capital Expenditures (CapEx) | $13.8M | $22.9M | — |
| Free Cash Flow (FCF) | $156.8M | $35.8M | -$206.3M |
| FCF Margin % | 21.1% | 3.4% | -19.7% |
| Return on Invested Capital (ROIC %) | 8.9% | -8.2% | — |
| Cash & Short-Term Equivalents | $205.4M | $99.5M | — |
| Total Debt (Short + Long Term) | $572.1M | $663.7M | — |
| Total Stockholders' Equity | $522.6M | $482.8M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR EBS.